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Targeted Knock-In Mice Expressing Mutations of CD28 Reveal an
Essential Pathway for Costimulation†
Lindzy F. Dodson,1,2‡ Jonathan S. Boomer,2‡ Christine M. Deppong,2 Dulari D. Shah,2 Julia Sim,3
Traci L. Bricker,2 John H. Russell,3 and Jonathan M. Green1,2*
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Washington University School of Medicine, St. Louis, Missouri 63110
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Despite extensive study, the role of phosphatidylinositol 3-kinase (PI3-kinase) activation in CD28 function
has been highly contentious. To definitively address this question, we generated knock-in mice expressing
mutations in two critical domains of the cytoplasmic tail of CD28. Mutation of the proximal tyrosine motif
interrupted PI3-kinase binding and prevented CD28-dependent phosphorylation of protein kinase B (PKB)/
Akt; however, there was no detectable effect on interleukin-2 (IL-2) secretion, expression of Bcl-XL, or on T-cell
function in vivo. Furthermore, we demonstrate that signaling initiated by the C-terminal proline motif is
directly responsible for tyrosine phosphorylation of phosphoinosotide-dependent kinase 1, protein kinase C,
and glycogen synthase kinase 3, as well as contributing to threonine phosphorylation of PKB. T cells mutated
in this domain were profoundly impaired in IL-2 secretion, and the mice had marked impairment of humoral
responses as well as less severe disease manifestations in experimental allergic encephalomyelitis. These data
demonstrate that the distal proline motif initiates a critical nonredundant signaling pathway, whereas direct
activation of PI3-kinase by the proximal tyrosine motif of CD28 is not required for normal T-cell function.
CD28 and T-cell receptor (TCR)-derived signals act syner-
gistically, leading to optimal T-cell proliferation, cytokine se-
cretion, and cell survival (for a review, see reference 32). The
importance of CD28 in vivo is evidenced by impaired re-
sponses of CD28-deficient mice in a number of model systems,
including allergic airway inflammation and experimental aller-
gic encephalomyelitis (EAE) (13, 34). In addition, the recent
development of inhibitors of CD28 as effective therapeutics for
autoimmune disease and transplant immunosuppression fur-
ther emphasizes the critical role of this receptor in human
disease (21, 57).
Despite extensive study, the biochemical mechanism(s) that
mediates CD28 function remains incompletely understood.
Specific motifs within the cytoplasmic tail of CD28 have been
identified that trigger distinct signaling pathways. Binding and
activation of Src family kinases to the distal proline motif
(sequence PYAP) initiates signaling, whereas the proximal ty-
rosine motif (sequence YMNM) binds and activates the p85
subunit of phosphatidylinositol 3-kinase (PI3-kinase) as well as
other adaptor proteins, including Grb2 and GADS (12, 27, 28,
33, 42, 48, 51). Studies have suggested that both motifs con-
tribute to CD28-dependent interleukin-2 (IL-2) secretion and
proliferation but that the upregulation of Bcl-XL is uniquely
dependent on PI3-kinase activation by the proximal tyrosine at
position 170 (11, 25, 43). The potential for extensive overlap
between pathways initiated by each motif exists, as well as
overlap between CD28 and TCR-derived signals, making it
unclear as to whether CD28 initiates any critical, nonredun-
dant signaling pathway.
We generated gene-targeted knock-in mice expressing either
wild-type CD28 or mutations in the proximal tyrosine-based
motif or the distal proline-based motif to determine the im-
portance of these both biochemically and functionally. Our
data demonstrate that the distal proline motif initiates an es-
sential signaling pathway required for normal regulation of
IL-2 secretion and CD28-dependent responses in vivo. Muta-
tion of this motif resulted in the failure to normally phosphor-
ylate phosphoinosotide-dependent kinase 1 (PDK1), glycogen
synthase kinase 3 (GSK3), and protein kinase C (PKC),
implicating these kinases as critical downstream mediators of
CD28 function. In contrast, mutation of the proximal tyrosine
motif resulted in no detectable defect in T-cell function, de-
spite impaired binding of the p85 subunit of PI3-kinase and a
lack of CD28-dependent serine phosphorylation of protein
kinase B (PKB/Akt). These data strongly suggest that loss of
the proximal tyrosine motif can be overcome by compensatory
pathways, whereas no such redundancy exists for signaling
initiated by the distal proline motif.
MATERIALS AND METHODS
Mice. CD28 knock-in mice were generated as previously described for CD28-
AYAA mice (20). A knock-in mouse expressing nonmutated CD28 was gener-
ated using a construct encoding wild-type CD28. For the CD28-Y170F knock-in
mice, oligonucleotide-directed site-specific mutagenesis was performed to gen-
erate a specific mutation (TAC to TTC) resulting in substitution of phenylala-
nine for the tyrosine at position 170. The sequence of the entire exon was verified
by direct sequence analysis. The construct was transfected into 129/Sv embryonic
stem cells (line RW4; provided by the Siteman Cancer Center, Washington
University, St. Louis, MO), and neomycin-resistant clones were screened for
homologous recombination by Southern blotting of BglII- and EcoRI-digested
DNA using 5 and 3 external probes, respectively (see Fig. S1 in the supple-
mental material). The mutation was confirmed by direct sequencing of exon IV
* Corresponding author. Mailing address: 660 S. Euclid Ave., P.O.
Box 8052, St. Louis, MO 63110. Phone: (314) 747-3591. Fax: (314)
362-8987. E-mail: jgreen@wustl.edu.
† Supplemental material for this article may be found at http://mcb
.asm.org/.
‡ L.F.D. and J.S.B. contributed equally to this work and should be
considered co-first authors.
 Published ahead of print on 27 April 2009.
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following PCR amplification of genomic DNA, as well as by restriction digestion
with Bsph1, as the mutation results in the generation of a new BspH1 site (data
not shown). Germ line transmission was verified by Southern blotting using both
5 and 3 external probes. The presence of the mutation was further confirmed
by reverse transcription-PCR amplification of the mRNA using primers specific
for exon III and the 3 untranslated region and direct sequence analysis as well
as restriction digestion of the PCR product. The mice were back-bred into
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME). Genetic background
was monitored by DNA microsatellite analysis (Rheumatic Diseases Speed Con-
genics Core, Washington University, St. Louis, MO) and confirmed to be 100%
C57BL/6J. The mice were also crossed to D011.10 OVA TCR transgenic mice
(generously provided by K. Murphy, Washington University School of Medicine,
St. Louis, MO) for five generations and then intercrossed to generate homozy-
gous mutants that were used for experiments. CD28-deficient mice were origi-
nally obtained from C. Thompson (University of Pennsylvania, Philadelphia).
C57BL/6J and BALB/c mice were purchased from Jackson Laboratories (Bar
Harbor, ME). All mice were housed under specific-pathogen-free conditions at
Washington University School of Medicine. All protocols were reviewed and
approved by the Washington University School of Medicine Animal Studies
Committee.
Antibodies. Anti-CD3ε (clone 145-2c11; hamster immunoglobulin G [IgG])
and all other fluorescently conjugated antibodies used for staining were pur-
chased from either eBioscience (San Diego, CA) or BD Biosciences (San Jose,
CA). For T-cell stimulations, anti-CD28 (clone 37.51; hamster IgG) was pur-
chased from BD Bioscience. For immunoprecipitation, anti-CD28 (clone PV-1;
hamster IgG) was purchased from Southern Biotechnology (Birmingham, AL).
For Western blotting, anti-CD28 (clone M2; goat IgG) was purchased from
R&D Systems (Minneapolis, MN). Antibodies directed against phosphoserine
PKB/Akt (S473; clone 193H12; rabbit IgG), phosphothreonine PKB/Akt (T308;
clone 244F9; rabbit monoclonal), total PKB/Akt (polyclonal rabbit IgG), phos-
FIG. 1. (A) Expression of CD28 on CD4 splenocytes and thymocytes from the wild-type and mutant knock-in mice. (B) CD4 and CD8
expression on splenocytes isolated from wild-type and CD28 mutant knock-in mice.
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pho-p44/42 mitogen-activated protein (MAP) kinase (Erk1/2 T202/Y204; rabbit
polyclonal), and total p44/42 MAP kinase (Erk1/2; rabbit polyclonal), phospho-
GSK3/ (S21/9; rabbit polyclonal), phospho-serine PDK1 (S241; rabbit poly-
clonal), total PDK1 (rabbit polyclonal), PI3-kinase p85 subunit (rabbit poly-
clonal), phospho-PKC (T538; rabbit polyclonal), and total PKC (rabbit
polyclonal) were all purchased from Cell Signaling (Danvers, MA). Phospho-
tyrosine PDK1 (Y9; rabbit polyclonal) was purchased from ECM Biosciences
(Versailles, KY). Anti-Bcl-XL (clone 2H12; mouse IgG) was purchased from
Southern Biotechnology (Birmingham, AL). Total GSK3/ (mouse IgG) was
purchased from Biosource International (Camarillo, CA). Murine CTLA4 Ig was
generously provided by Wyeth Pharmaceuticals.
Proliferation and cytokine assays. Bulk splenocytes were isolated from 6- to
8-week-old mice of each genotype by density gradient centrifugation over Lym-
pholyte-M (Cedarlane Labs, Ontario, Canada), plated at 1  105 cells per well
in round-bottom 96-well tissue culture plates, and stimulated as indicated for
48 h. For proliferation, each well was pulsed with 1 Ci tritiated thymidine
overnight and harvested the following morning. For IL-2 assays, supernatants
were harvested and IL-2 was determined by enzyme-linked immunosorbent assay
(ELISA; R&D Systems, Minneapolis, MN). Splenocytes from mice on the
DO11.10 OVA TCR transgenic background were incubated with OVA(323–339)
peptide for 72 h prior to pulsing with tritiated thymidine. All conditions were
plated in quadruplicate and the means  standard deviations of the replicate
wells are reported. All experiments were repeated a minimum of three times, and
representative data are presented.
For determination of proliferation in vivo, splenocytes from mice of each
genotype on the DO11.10 background were isolated and labeled with 2.5 M
carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Invitrogen
Corp., Carlsbad, CA). A total of 5  106 labeled cells were transferred by
intravenous (i.v.) injection into naïve BALB/c mice. The following day, the mice
were injected intraperitoneally (i.p.) with 50 g OVA adsorbed to 2 mg alum.
Three days after OVA immunization, the mesenteric lymph node cells were
isolated and stained with allophycocyanin (APC)-conjugated CD4, phycoerythrin
(PE)-conjugated KJ1-26 monoclonal antibody (recognizing the clonotypic TCR),
and the CFSE profiles of the CD4/KJ1-26-positive cells were determined by
flow cytometry.
For measurement of IL-4, splenocytes were isolated from mice of each genotype
on the DO11.10 background and stimulated with 0.3 M OVA(323-339) in the pres-
ence of recombinant murine IL-4 and anti-IL-12 for 7 days. The cells were then
washed and rested overnight in fresh medium without cytokine or antibody and
restimulated 24 h later with peptide antigen for 48 h. IL-4 in the culture supernatant
was determined by ELISA (R&D Systems, Minneapolis, MN).
Radiation-induced cell death. Splenic T cells were purified from mice of each
genotype by negative selection using the Stem Sep mouse T-cell enrichment kit
(Stem Cell Technologies, Vancouver, BC, Canada) and an AutoMacs magnetic
separator (Miltenyi Biotech, Auburn, CA). The cells were rested overnight in
serum-free medium and then left either unstimulated or stimulated with anti-
CD3 alone or with anti-CD3 and anti-CD28. The cells were then washed and
resuspended at 2  105 cells/ml in serum-free medium and exposed to 	-irradi-
ation (3 Gy). At 24 h following irradiation, viability of the T-cell population was
determined by staining with anti-CD4–PE, annexin-APC, and 7-amino-actino-
mycin D and analyzed by flow cytometry.
Allergic airway inflammation. Mice were immunized i.p. on days 0 and 7 with
8 g OVA absorbed to 2 mg alum (Sigma-Aldrich, St. Louis, MO) as previously
described (34, 35). On day 14, the mice were intranasally challenged with 50 l
FIG. 2. Proliferation and IL-2 secretion depend on the distal proline motif and not the proximal tyrosine motif. Splenocytes were isolated from
mice of each genotype and stimulated with graded doses of anti-CD3 alone or in combination with anti-CD28 antibody (1 g/ml). (A) Proliferation
was determined by tritiated thymidine incorporation. (B) IL-2 was measured in culture supernatants by ELISA. (C) Cells were stimulated with
PMA (5 ng/ml) alone or in combination with anti-CD28 (1 g/ml), and proliferation was determined by tritiated thymidine incorporation.
(D) Splenocytes were isolated from mice heterozygous for wild-type or mutant CD28 on the CD28
/
 background, therefore expressing only one
CD28 allele, and stimulated with anti-CD3 (0.1 g/ml) alone, in combination with CTLA4 Ig (10 g/ml), or with both CTLA4 Ig and increasing
doses of anti-CD28 (0.03, 0.3, or 1.0 g/ml). Proliferation was determined by tritiated thymidine incorporation. All experiments were repeated a
minimum of three times and representative data are presented. Data are the means  standard deviations of quadruplicate wells.
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of 2% OVA in phosphate-buffered saline and specimens were collected on the
third day following challenge. Bronchoalveolar lavage was performed by intra-
tracheal installation of 1% bovine serum albumin in phosphate-buffered saline.
Cell differentials were performed on cytospin preparations stained with a mod-
ified Wright-Giemsa stain. For histology, the lungs were inflated with neutral
buffered formalin to 25 cm water pressure and fixed overnight. Samples were
progressively dehydrated in ethanol and processed for sectioning and hematox-
ylin and eosin (H&E) staining. Serum was collected at the time of sacrifice, and
antigen-specific immunoglobulin titers were determined by ELISA as previously
described (10). Spleens were also harvested and frozen in Tissue-Tek optimal
cutting temperature compound (Sakura Finetek, Torrance, CA) on dry ice.
Frozen sections were prepared, fixed in acetone, and stained with peanut agglu-
tinin-biotin and rat anti-mouse IgD followed by detection with alkaline phos-
phatase-streptavidin and goat anti-rat IgG (HL)–horseradish peroxidase to
identify germinal centers. Sections were examined for the number of germinal
centers, and the mean number of germinal centers per 10 field was determined.
Experimental allergic encephalomyelitis. Mice were injected subcutaneously
with 50 g myelin oligodendrocyte peptide in incomplete Freund’s adjuvant and
500 g mycobacterium on day zero. Pertussis toxin (300 ng) was injected i.v. on
days 1 and 3. Mice were monitored daily for symptoms and scored as follows: 0,
normal without overt signs of disease; 1, limp tail; 2, hind limb weakness; 3,
paralysis of one hind limb; 4, paralysis of both hind limbs; 5, moribund state,
death due to EAE, or euthanized for humane reasons. Central nervous system
(CNS) tissues were removed from the mice at the termination of the experiment
and frozen, sectioned, and stained with hematoxylin and eosin for histological
analysis.
Determination of Bcl-XL expression. For determination of Bcl-XL expression,
splenocytes were isolated and stimulated for 24 h. Bcl-XL expression was mea-
sured by intracellular staining and flow cytometry or by Western blotting as
previously described (20). For flow cytometry, the cells were stained with APC-
conjugated anti-CD4, peridinin chlorophyll protein-conjugated anti-CD8, and
PE-conjugated Bcl-XL, and expression levels of CD4- and CD8-positive cells are
presented.
Western blotting and immunoprecipitation studies. Purified splenic T cells
were isolated by negative selection using immunolabeling and magnetic bead
separation as described above. Following purification the cells were rested at a
density of 4  106 cells/ml overnight at 37°C, 5% CO2 in medium containing 2%
fetal bovine serum. The following day, the cells were rested in serum-free me-
dium on ice for 1 h at a density of 2  106 cells/100 l and then incubated with
primary antibody(s) at the indicated concentration for 30 min on ice. The cells
were then pelleted and resuspended in prewarmed serum-free medium contain-
ing 4.5 g/ml each of anti-Syrian hamster IgG and anti-Armenian hamster IgG
(Jackson Immunoresearch, West Grove, PA) and incubated at 37°C for the
indicated times. The cells were then pelleted, resuspended, and boiled in 25 l
4 sodium dodecyl sulfate (SDS) loading buffer for 10 min. Proteins were
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred
to polyvinylidene difluoride membrane, and analyzed by Western blotting. Den-
sitometry was performed using ImageJ analysis software (National Institutes of
Health, Bethesda, MD). The integrated pixel density was determined for each
band and the density of the phosphorylated band was normalized to that of the
total protein. The normalized result was then divided by that obtained for the
unstimulated condition, and the ratio of the stimulated to unstimulated condition
was determined.
For immunoprecipitation, splenocytes were harvested from mice of each ge-
notype in the DO11.10 background and cultured with 3 M OVA(323–339) pep-
tide for 72 h. Equal numbers of cells from each genotype were collected and
lysed in radioiummunoprecipitation assay (RIPA) buffer containing both pro-
tease and phosphatase inhibitors. After clarification of the insoluble material by
high-speed centrifugation, the supernatants were collected and brought to 500 l
with lysis buffer. Five micrograms of anti-CD28 (clone PV-1) or isotype control
antibody was added to each sample and incubated at 4°C with rocking overnight.
Protein G-Sepharose beads were preincubated with 5 g AffiniPure goat anti-
FIG. 3. Proliferation and IL-4 secretion in response to antigen is impaired in the CD28-AYAA knock-in mice but not CD28-Y170F mice.
Splenocytes were isolated from mice of each genotype in the DO11.10 background. (A and B) Cells were stimulated with OVA(323–339) peptide
and proliferation was measured after 72 h by tritiated thymidine incorporation. (C) Cells were cultured with OVA(323–339) peptide plus recombinant
IL-4 and anti-IL-12 for 7 days. The cells were then washed, rested overnight, and restimulated with peptide for 48 h. The culture supernatant was
collected and IL-4 content was assayed by ELISA. (D) Splenocytes were isolated from mice of each genotype and labeled with CFSE. A total of
5  106 cells were then injected i.v. into naïve BALB/c mice. The following day, the recipient mice were injected with OVA-alum (50 g) i.p.
Mesenteric lymph nodes were collected 72 h later, stained for CD4 and KJ1-26, and analyzed by flow cytometry. The CFSE profile of the
KJ1-26-positive cells is presented. Representative data of three independent experiments are presented.
VOL. 29, 2009 NONREDUNDANT SIGNALING PATHWAYS INITIATED BY CD28 3713
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hamster IgG for 1 h and washed, and 30 l was added to each sample and further
incubated for 45 min at 4°C with gentle rocking. The beads were then collected
by centrifugation, washed four times with RIPA buffer, resuspended, and boiled
in 30 l of 4 SDS sample buffer for analysis. All autoradiographs were scanned
on a Powerlook 1120 scanner (UMAX Corporation, Dallas, TX) using Silverfast
Ai software (Lasersoft Imaging, Longboat Key, FL). Final images were pro-
cessed with Adobe Photoshop software (Adobe Systems Inc., San Jose, CA).
RESULTS
IL-2 secretion and proliferation depend on the distal proline
motif but not the proximal tyrosine motif of CD28. To deter-
mine the effects of specific mutations in the cytoplasmic do-
main of CD28 on T-cell function, we generated knock-in mice
expressing either wild-type CD28 (CD28/), CD28 with a
phenylalanine-for-tyrosine substitution in the proximal motif
at position 170 (CD28-Y170F), or CD28 with alanine-for-pro-
line substitutions in the distal motif at positions 187 and 190
(CD28-AYAA) (see Fig. S1 in the supplemental material). All
strains were bred to homozygosity of the knock-in allele and
backcrossed into the C57BL/6 background. The CD28/
knock-in mice were extensively compared to commercially pur-
chased C57BL/6J mice, and no differences were detected. Un-
less otherwise indicated, the wild-type knock-in mice were used
as controls in all experiments. CD28-deficient mice were bred
and maintained as previously described (24).
All strains expressed CD28 at similar levels and on both
thymocytes and peripheral T cells (Fig. 1A). Activation-in-
duced upregulation of CD28 expression was also similar be-
tween mutant and wild-type strains (data not shown). In addi-
tion, we detected no differences in the number and distribution
of CD4 and CD8 cells in either the spleen or thymus of all
genotypes (Fig. 1B and data not shown). Therefore, neither the
specific mutations nor the genetic manipulation detectably al-
tered T-cell development or CD28 expression.
Given the hallmark importance of CD28 in T-cell prolifer-
ation and IL-2 secretion, we first examined the effect of the
mutations on these responses. CD28/, CD28-Y170F, and
CD28-AYAA cells all proliferated to similar levels following
stimulation, whereas the CD28-deficient mice had markedly
impaired proliferation (Fig. 2A). There was no defect observed
in IL-2 secretion in T cells from the CD28-Y170F knock-in
mice, in contrast to the CD28-AYAA mutation and CD28-
deficient mice, which both had greatly reduced IL-2 secretion
(Fig. 2B). When activated with phorbol myristate acetate
(PMA) and anti-CD28, the wild-type and Y170F cells prolif-
erated vigorously whereas the CD28-deficient and CD28-
AYAA mouse cells failed to respond. All strains proliferated
in response to PMA plus ionomycin stimulation (Fig. 2C and
data not shown).
Our previous work had demonstrated that both the level of
CD28 expression and the degree of receptor engagement were
important determinants of whether cells expressing the mutant
allele mounted a normal or reduced proliferative response
(20). This was evident by examination of cells from mice ex-
pressing only one mutant allele on the CD28-deficient back-
ground and by using limiting amounts of anti-CD28 antibody.
However, in contrast to the CD28-AYAA mice, there was no
detectable difference between cells expressing one copy versus
two copies of the Y170F allele at either low or high levels of
CD28 cross-linking (Fig. 2D).
To examine additional another physiologic antigen receptor
engagement, we bred the mice onto the DO11.10 TCR trans-
FIG. 4. Neither the proximal nor distal motif is absolutely required for T-cell survival or Bcl-XL expression. (A) Splenocytes were cultured in
medium or stimulated with anti-CD3 alone (1.0 mg/ml) or with anti-CD28 (1.0 mg/ml). After 48 h, the cells were lysed and Bcl-XL expression levels
were determined by Western blotting. The arrow points to the specific band. (B) Splenocytes from mice of each genotype were isolated and
cultured either with medium alone or stimulated with anti-CD3 (0.1 or 1.0 g/ml) and anti-CD28 (0.1 or 1.0 g/ml) in the presence of CTLA4 Ig
(10 g/ml) for 48 h. The cells were surface stained with anti-CD4 or anti-CD8 followed by an intracellular stain for Bcl-XL. Shown is the Bcl-XL
expression of CD4 (top row) and CD8 (bottom row) cells. (C) Purified T cells were stimulated as indicated for 18 h and then washed, and equal
numbers of cells were exposed to 	-irradiation (3 Gy). After 24 h, cell viability was determined by staining with CD4-PE, annexin V-APC, and
7-amino-actinomycin D (7-AAD) and analyzed by flow cytometry. Representative data of three independent experiments are presented.
FIG. 5. p85 binding and serine phosphorylation of PKB/Akt are
impaired in the CD28-Y170F mutant. (A and B) Splenocytes from
mice of each genotype in the DO11.10 background were isolated and
cultured with OVA(323–339) peptide for 72 h. Equal numbers of cells
were isolated and lysed in RIPA buffer, and CD28 was immunopre-
cipitated. The immunoprecipitated protein was separated by SDS-
polyacrylamide gel electrophoresis, transferred to polyvinylidene di-
fluoride, and blotted for p85 or CD28. Arrows indicate the specific
bands. (C and D) Purified T cells were isolated from mice of each
genotype and cultured with either medium alone or stimulated for 5
min with anti-CD3 (0.1 g/ml) alone or in combination with anti-CD28
(8 g/ml) with cross-linking antibodies as described in Materials and
Methods. Following stimulation, Western blot analysis was performed
for each protein as indicated. Densitometry was performed as de-
scribed in Materials and Methods, and the ratio with the unstimulated
control is shown.
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genic background and measured proliferation and cytokine
secretion in response to peptide antigen. Stimulation with
OVA(323–339) peptide led to similar proliferative responses in
cells expressing wild-type or CD28-Y170F alleles (Fig. 3A). In
contrast, T cells expressing CD28-AYAA had slightly, but re-
producibly, reduced proliferation (Fig. 3B). IL-2 and IL-4 se-
cretion was also reduced in cultures from CD28-AYAA-ex-
pressing cells but not from the CD28-Y170F cultures (Fig. 3C
and data not shown). To examine proliferation in vivo we
adoptively transferred CFSE-labeled splenocytes isolated from
each genotype on the DO11.10 background into naïve BALB/c
mice. Only the cells isolated from CD28-deficient mice mani-
fested impaired proliferation in vivo; however, fewer cells from
the CD28-AYAA mice divided beyond four generations than
in the wild type or CD28-Y170F, although the significance of
this observation is not clear (Fig. 3D).
The Y170F mutation does not alter Bcl-XL expression or
T-cell survival. The proximal tyrosine-based motif has been
shown by several groups to be essential for CD28-induced
Bcl-XL upregulation, which has been shown to improve T-cell
survival (9, 11, 43). Therefore, we determined both Bcl-XL
expression and resistance to an apoptotic stimulus in each of
the CD28 knock-in mouse groups. Surprisingly, Bcl-XL expres-
sion was not impaired in cells from the CD28-Y170F knock-in
mice (Fig. 4A and B). To determine if this was related to the
strength of the signal through either CD3 or CD28, we tested
both low and high doses of each antibody and determined
expression in both CD4- and CD8-positive cells. As expected,
there was no CD28-dependent upregulation in the CD28-de-
ficient mice. Cells from both knock-in strains upregulated
Bcl-XL expression comparably to cells expressing wild-type
CD28 at both 24 and 48 h following activation (Fig. 4A and B
and data not shown). We directly tested the resistance of the
cells to radiation-induced apoptosis (Fig. 4C). No difference
was detected between the cells expressing CD28/, CD28-
Y170F, or CD28-AYAA, whereas there were markedly fewer
live CD28
/
 cells. We also measured the survival of resting
CD4 T cells in culture over time. After 96 h, 83% of CD28/
cells were viable as determined by propidium iodide staining.
In contrast 68% of CD28
/
 cells were alive. Survival of the
CD28-AYAA and CD28-Y170F cells was 85% and 83%, re-
spectively. Thus, neither mutation altered cell survival, sug-
gesting that no single motif was individually responsible for
mediating the antiapoptotic effect of CD28.
PI3-kinase binding and PKB/Akt phosphorylation are im-
paired in the CD28-Y170F mutant but are intact in the CD28-
AYAA mutant. The p85 subunit of PI3-kinase binds to phos-
phorylated tyrosine at position 170, although it may also bind
other sites in CD28 (44, 51). We directly assayed whether
binding was preserved in the knock-in mice. The p85 subunit of
PI3-kinase was coimmunoprecipitated with CD28 in lysates
from CD28/ or CD28-AYAA cells, but not from CD28
/

cells or CD28-Y170F-expressing cells (Fig. 5A and B). Greater
amounts of CD28 were immunoprecipitated from the activated
cells, consistent with upregulation of the receptor upon cell
activation, but this was not different between wild-type and
mutant cells. All samples contained similar amounts of total
p85 as determined by Western blotting of whole-cell lysates
(data not shown).
Activation of PKB/Akt has been shown to be a consequence
of CD28-dependent activation of PI3-kinase and is thought to
be essential for upregulation of Bcl-XL expression (29, 46).
FIG. 6. Phosphorylation of PKC, GSK3, and PDK1 depends on the distal proline motif but not the proximal tyrosine motif of CD28, whereas
threonine phosphorylation of PKB requires both motifs. Purified T cells were isolated from mice of each genotype and cultured with either medium
alone or stimulated for 5 min with the indicated doses of anti-CD3 alone or in combination with anti-CD28 (8 g/ml) with cross-linking antibodies
as described in Materials and Methods. Following stimulation, Western blot analysis was performed for each protein as indicated. Arrows indicate
the specific bands. The lane order for the CD28-AYAA and CD28-Y170F pT-PKB and total PKB samples was modified from the original blot by
using Adobe Photoshop software to be consistent with the other samples presented in this figure. In the original gel, the samples were loaded with
CD28-AYAA in lanes 1 to 4 and CD28-Y170F in lanes 5 to 8. Densitometry was performed as described in Materials and Methods, and the ratio
with the unstimulated control is shown.
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CD28-dependent serine phosphorylation of PKB/Akt was ev-
ident in cells from CD28/ mice at suboptimal levels of anti-
CD3 stimulation but was absent in the cells expressing the
CD28-Y170F mutant (Fig. 5C and D). Phosphorylation of
PKB/Akt was preserved in the CD28-AYAA knock-in mutant
cells, although at a slightly reduced intensity. We also exam-
ined more distal signaling by examining activation of the MAP
kinase extracellular signal-regulated kinase (ERK). CD28 co-
stimulation augmented ERK phosphorylation in all genotypes
except for CD28
/
 (Fig. 5C and D).
Phosphorylation of the downstream kinases, PDK1, PKC,
and GSK3, depends on the distal proline motif but not the
proximal tyrosine motif of CD28. Both PKC and GSK3 have
been shown to be important elements of the signal transduc-
tion cascade initiated by CD28. PKC family members can
phosphorylate and activate GSK3, which results in nuclear
trapping of NFAT, leading to prolonged transcription of
NFAT responsive genes (5, 15, 18, 23, 41, 56). PKC signaling
also contributes to the regulation of Bcl-XL expression (39).
Cells expressing wild-type CD28 exhibited a CD28-dependent
phosphorylation of PKC and GSK3, as did the CD28-
Y170F-expressing cells (Fig. 6). However, CD28-dependent
phosphorylation of PCK and GSK3 was not evident in
CD28-AYAA or CD28-deficient cells, although at higher
doses of anti-CD3 both proteins were phosphorylated in the
absence of CD28 ligation (Fig. 6).
We also examined GSK3 and ERK phosphorylation in
each strain following stimulation with a low (0.1 g/ml) or high
(2.0 g/ml) dose of anti-CD3 or anti-CD28 at 5, 20, and 60
min. CD28-dependent phosphorylation of GSK3 was detect-
able only at 5 min in cells from CD28/ and CD28-Y170F-
expressing cells following low-dose stimulation but was not
detectable in the CD28-deficient or CD28-AYAA-expressing
T cells (data not shown). ERK phosphorylation was detected
at 5 min but was not sustained. However, there may be impor-
tant kinetic differences in signaling in vivo that are not detect-
able by this in vitro assay system. Previous work had suggested
that PDK1 is important in signals initiated by the distal proline
motif as well as in PI3-kinase-dependent pathways, thereby
providing a potential linkage between signaling initiated by
these motifs (3, 40). PDK1 has two phosphorylation sites,
serine 241 (S241) and tyrosine 9 (Y9) (54). S241 is thought to
be regulated primarily by autophosphorylation, whereas Y9 is
dependent on upstream kinase activity. Consistent with this,
we did not detect any effect of CD28 signaling on phosphory-
lation of the S241 residue (data not shown). In contrast, phos-
phorylation of Y9 was augmented by CD28 and was dependent
upon the distal proline-based motif but not the proximal ty-
 M
FIG. 7. Allergic airway inflammation in the CD28 knock-in mice. Mice of each genotype were sensitized and given an inhaled challenged of
OVA. (A and B) Total cell number (A) and differential analysis of cells (B) recovered in the bronchoalveolar lavage fluid. Mac, macrophages;
Lymph, lymphocytes; Neut, neutrophils; Eos, eosinophils. (C) Histologic sections of lung tissue stained with H&E. (D) OVA-specific IgG1 titers
in the serum of mice of each genotype following systemic sensitization. (E) Germinal center number as determined by staining sections of spleens
with peanut agglutinin and anti-IgD.
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rosine motif (Fig. 6). PKB/Akt is an important substrate of
PDK1, phosphorylating it on T308 (1). Although T308 phos-
phorylation was CD28 dependent, it was decreased in both
mutant strains, suggesting both motifs are necessary for this
site to be normally regulated (Fig. 6).
The distal proline-based motif, but not the proximal ty-
rosine-based motif, regulates humoral immunity in allergic
airway inflammation and disease severity in EAE. We studied
how the knock-in mice responded to allergic airway inflamma-
tion and EAE, two distinct CD28-dependent disease models
(13, 34). In the allergic airway inflammation model, only the
CD28-deficient mice had a reduction in lung inflammation, as
assayed by bronchoalveolar lavage cell counts and differentials
and histology (Fig. 7A, B, and C). Both germinal center for-
mation and isotype switching require CD28. As previously re-
ported, both were markedly impaired in the CD28-AYAA
mice and the CD28
/
 mice; however, no defect was observed
in the CD28-Y170F mice (Fig. 7D and E).
Experimental autoimmune encephalomyelitis results from
self-reactive T cells that infiltrate the CNS and cause demyeli-
nation and a progressive ascending paralysis that models the
human disease multiple sclerosis (16, 22). CD28-deficient mice
manifest less severe disease than wild-type mice, highlighting
the importance of this pathway in the response. When we
tested the CD28-Y170F and CD28-AYAA mice in this model,
we found that the CD28-AYAA mice had attenuated disease,
whereas the CD28-Y170F mice manifested a clinical score
similar to wild-type mice (Fig. 8). Despite differences in the
clinical score, all genotypes, with the exception of the CD28-
deficient mice, had inflammatory infiltrates in the CNS
(Fig. 8D).
DISCUSSION
CD28 is unique among costimulatory receptors in its po-
tency to increase IL-2 secretion. Our data demonstrate that net
IL-2 secretion is critically dependent on the distal proline motif
of CD28 but not on the proximal tyrosine motif. CD28 regu-
lates IL-2 by both transcriptional and posttranscriptional
mechanisms (19, 30, 37, 53). Transcriptional control is exerted
by the binding of multiple transcription factors to the IL-2
locus, including NFAT, AP-1, and NF-B. Multiple pathways
converge at these transcription factors, making them likely
points of signal integration.
Among the many signaling intermediates downstream of
CD28, recent data have emphasized the importance of PKB/
Akt (29, 31, 40, 46, 58). PKB activation by CD28 is mediated by
binding of PI3-kinase to the proximal tyrosine motif and is
thought to be essential for upregulation of Bcl-XL as well as
important in the regulation of IL-2 and gamma interferon
secretion (31, 43, 46). Consistent with this, we found that the
Y170F mutant failed to bind the p85 subunit of PI3-kinase and
did not phosphorylate PKB on Ser473. However, despite these
defects, expression of Bcl-XL was normal in this mutant. Thus,
our data strongly suggest that there are at least two overlap-
ping pathways that can lead to Bcl-XL expression. One is me-
FIG. 8. Disease severity in EAE is reduced in CD28-AYAA mice. Mice of each genotype were immunized with myelin oligodendrocyte protein
as described in Materials and Methods. The clinical score was determined in a blinded fashion. For each experiment 8 to 10 mice of each genotype
were included. Independent experiments were performed comparing CD28/ and CD28
/
 mice with either CD28-Y170F (A) or CD28-AYAA
(B) or all genotypes together (C). For clarity, error bars are not shown in this panel. There were no statistically significant differences in disease
severity for the CD28/ and CD28-Y170F mice at any point. At later time points, there was a significant difference between the CD28-AYAA
and CD28
/
 mice. (D) Representative sections of brain stained with H&E.
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diated by the proximal tyrosine-based motif binding PI3-kinase
and subsequent activation of PKB/Akt. However, when this
pathway is no longer operative, redundant pathways are suffi-
cient to drive Bcl-XL expression.
Full activation of PKB/Akt requires not only serine phos-
phorylation but also phosphorylation by PDK1 at T308 (1, 7,
14). PDK1, in part, depends upon PI3-kinase for activation.
Binding of PIP2 facilitates the membrane localization of PDK1
and subsequent autophosphorylation of S241. However, ty-
rosine phosphorylation of PDK1 by Src kinases is an additional
regulatory mechanism (45). The importance of CD28 in ty-
rosine phosphorylation of PDK1 has not previously been re-
ported. Given that PDK1 is implicated in activating PKB/Akt
by phosphorylation of T308, we also examined this phosphor-
ylation event in the knock-in strains. When examined in our
knock-in mice, we found a CD28 dependence to tyrosine phos-
phorylation of PDK1 and that this required the distal proline
motif. CD28 did regulate T308 phosphorylation of PKB, how-
ever; both mutants were defective in this, suggesting that the
pathways cooperate to fully activate PKB. These data support
a model in which CD28 can activate PKB by multiple mecha-
nisms, including via Lck-mediated activation of PDK1.
PKC, a nonconventional member of the protein kinase C
family, has been demonstrated to be a critical downstream
effector of CD28 (50). We found that CD28-dependent phos-
phorylation of PKC was defective only in the CD28-AYAA
and CD28-deficient mice. PKC serves a nonredundant func-
tion in T-cell activation, being important in NF-B-, AP-1-,
and possibly NFAT-mediated activation of IL-2 gene transcrip-
tion (26, 36, 47, 52). In addition to its effect on IL-2, PKC also
regulates Bcl-XL expression (39). PKC-deficient mice are un-
able to upregulate Bcl-XL in response to CD3/CD28 stimula-
tion, and ectopic expression of PKC can drive expression of a
Bcl-XL reporter via NF-B and AP-1 transcription factors.
Thus, the profound defect in IL-2 observed in the CD28-
AYAA knock-in mice is consistent with a failure to activate
PKC. Furthermore, preserved activation of PKC in the
CD28-Y170F mutant suggests that this pathway might com-
pensate for defective PKB/Akt activation and mediate expres-
sion of Bcl-XL.
Phosphorylation of PKC occurs at several sites and can be
potentially mediated by several kinases, including PKB/Akt,
PDK1, and Lck (6, 8, 17, 38). Our data demonstrate that
phosphorylation of T538 depends on the distal proline motif,
suggesting an important role for PDK1 in activating PKC. In
addition, the proximal tyrosine motif and PI3-kinase activation
have been implicated in the normal activation and localization
of PKC. When this motif was disrupted, PKC was not re-
cruited to the cSMAC and CD28-dependent transcriptional
upregulation of IL-2 gene expression was lost (49). However,
FIG. 9. Model of CD28 signaling pathways initiated by the distal and proximal motifs. Pathways mediated by the proximal tyrosine motif are
initiated by the binding of the p85 subunit of PI3-kinase, leading to S473 phosphorylation of PKB/AKT, which can activate gene transcription
through NF-B. Additionally, the distal proline motif activates Lck, which in turn results in tyrosine phosphorylation of PDK1. PDK1 can then
phosphorylate PKB on T308 as well as PKC on T538. Phosphorylation of GSK3 is also dependent on the distal proline motif, perhaps through
PKC. Both PKC phosphorylation and GSK phosphorylation lead to increased gene transcription through NF-B, NFAT, and AP-1. The
critical, nonredundant signaling pathway is primarily provided by the distal proline motif, in that mutation of the proximal tyrosine motif does not
functionally impair T-cell responses, whereas mutation of the proline severely impairs CD28 function.
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there was no change in net IL-2 secretion. As we did not
directly examine IL-2 gene transcription or the localization of
PKC, we cannot exclude these effects, and the alterations we
observed in IL-2 secretion remain consistent with these results.
Recently, GSK3 has been implicated in CD28 signaling (4,
15, 58). Phosphorylation of the regulatory serine residue of
GSK3 results in its inactivation (2). Active GSK3 promotes
the nuclear export of the transcription factor NFAT; thus, its
inactivation by phosphorylation promotes persistence of
NFAT in the nucleus and increased transcription of NFAT-
regulated genes (15). When examined in the knock-in mutant
strains, GSK3 phosphorylation was preserved in the CD28-
Y170F mutant but was absent in the CD28-AYAA mutant.
Thus, one mechanism by which the proline mutant might im-
pair IL-2 gene expression is through the failure to properly
regulate NFAT.
Both PKB/Akt and PKC isoforms have been implicated in
phosphorylating GSK3; however, despite impaired activation
of PKB/Akt, GSK3 phosphorylation remained intact in the
CD28-Y170F mutant (5, 18, 23, 55, 56). Thus, alternative ki-
nases capable of regulating GSK3 must remain operative. It
has been demonstrated in several systems that members of the
PKC family are able to phosphorylate GSK3, although we are
unaware of direct evidence demonstrating this for PKC (18,
23). Nonetheless, our data are consistent with a role for PKC
in the regulation of GSK3.
In vitro systems are necessarily reductionist and as such may
not accurately reflect events that occur in vivo. Using two
independent models of T-cell immunity, we found that only the
CD28-AYAA and CD28-deficient mice manifested alterations
in T-cell responses in vivo. There was a profound defect in
humoral responses in the CD28-AYAA mice but not the
CD28-Y170F mice in an allergic airway inflammation model.
Similarly, there was a marked reduction in EAE disease sever-
ity in the CD28-AYAA mice but normal clinical responses in
the CD28-Y170F mice. In both models, the defect in the
CD28-AYAA mice was not as severe as that observed in the
CD28-deficient mice, suggesting residual receptor function.
The CD28-AYAA mice had evidence of tissue inflammation,
but disease severity was lessened. This would be consistent
with intact cell recruitment but impaired effector function.
Nonetheless, the in vivo observations are consistent with our in
vitro experiments demonstrating impairment in only the
CD28-AYAA mutation.
Taken together, our data strongly support a model for CD28
signaling and function in which two partially overlapping bio-
chemical pathways exist (Fig. 9). In the wild-type setting, PI3-
kinase is activated by binding to the proximal tyrosine motif,
resulting in serine phosphorylation and activation of PKB/Akt.
Concomitantly, activation of Lck by the distal proline domain
results in the tyrosine phosphorylation of PDK1, which in turn
also acts on PKB/Akt. Our data demonstrate that phosphory-
lation of PKC and GSK3 requires the proline motif and
suggest that PDK1 is upstream of these effects, although we do
not exclude a role for other upstream kinases. Importantly, we
identify PDK1 as a point capable of linking signaling pathways
initiated by the proximal tyrosine-based and distal proline-
based motifs. Although published data suggest that there is
significant cross talk in both directions of this pathway, our
data suggest that in fact such compensation is predominantly
unidirectional, as only the distal proline mutant manifests a
detectable phenotype.
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